Journal of Experimental & Clinical Cancer Research最新文献

筛选
英文 中文
Aptamer-functionalized triptolide with release controllability as a promising targeted therapy against triple-negative breast cancer. 具有释放可控性的七聚物功能化三苯氧胺是一种治疗三阴性乳腺癌的前景广阔的靶向疗法。
IF 11.4 1区 医学
Journal of Experimental & Clinical Cancer Research Pub Date : 2024-07-25 DOI: 10.1186/s13046-024-03133-5
Yao Chen, Jirui Yang, Chuanqi Wang, Tianbao Wang, Yingjie Zeng, Xiao Li, Yi Zuo, Hongyu Chen, Chaozheng Zhang, Yuening Cao, Chen Sun, Maolin Wang, Xiujun Cao, Xian Ge, Yilan Liu, Ge Zhang, Yun Deng, Cheng Peng, Aiping Lu, Jun Lu
{"title":"Aptamer-functionalized triptolide with release controllability as a promising targeted therapy against triple-negative breast cancer.","authors":"Yao Chen, Jirui Yang, Chuanqi Wang, Tianbao Wang, Yingjie Zeng, Xiao Li, Yi Zuo, Hongyu Chen, Chaozheng Zhang, Yuening Cao, Chen Sun, Maolin Wang, Xiujun Cao, Xian Ge, Yilan Liu, Ge Zhang, Yun Deng, Cheng Peng, Aiping Lu, Jun Lu","doi":"10.1186/s13046-024-03133-5","DOIUrl":"10.1186/s13046-024-03133-5","url":null,"abstract":"<p><p>Targeted delivery and precise release of toxins is a prospective strategy for the treatment of triple-negative breast cancer (TNBC), yet the flexibility to incorporate both properties simultaneously remains tremendously challenging in the X-drug conjugate fields. As critical components in conjugates, linkers could flourish in achieving optimal functionalities. Here, we pioneered a pH-hypersensitive tumor-targeting aptamer AS1411-triptolide conjugate (AS-TP) to achieve smart release of the toxin and targeted therapy against TNBC. The multifunctional acetal ester linker in the AS-TP site-specifically blocked triptolide toxicity, quantitatively sustained aptamer targeting, and ensured the circulating stability. Furthermore, the aptamer modification endowed triptolide with favorable water solubility and bioavailability and facilitated endocytosis of conjugated triptolide by TNBC cells in a nucleolin-dependent manner. The integrated superiorities of AS-TP promoted the preferential intra-tumor triptolide accumulation in xenografted TNBC mice and triggered the in-situ triptolide release in the weakly acidic tumor microenvironment, manifesting striking anti-TNBC efficacy and virtually eliminated toxic effects beyond clinical drugs. This study illustrated the therapeutic potential of AS-TP against TNBC and proposed a promising concept for the development of nucleic acid-based targeted anticancer drugs.</p>","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":null,"pages":null},"PeriodicalIF":11.4,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11270970/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
m6A-mediated lnc-OXAR promotes oxaliplatin resistance by enhancing Ku70 stability in non-alcoholic steatohepatitis-related hepatocellular carcinoma. m6A 介导的 lnc-OXAR 通过增强非酒精性脂肪性肝炎相关肝细胞癌中 Ku70 的稳定性,促进奥沙利铂耐药性的产生。
IF 11.4 1区 医学
Journal of Experimental & Clinical Cancer Research Pub Date : 2024-07-25 DOI: 10.1186/s13046-024-03134-4
Zhu Lin, Zhenkun Huang, Jiliang Qiu, Yunxing Shi, Dinglan Zuo, Zhiyu Qiu, Wei He, Yi Niu, Yunfei Yuan, Binkui Li
{"title":"m<sup>6</sup>A-mediated lnc-OXAR promotes oxaliplatin resistance by enhancing Ku70 stability in non-alcoholic steatohepatitis-related hepatocellular carcinoma.","authors":"Zhu Lin, Zhenkun Huang, Jiliang Qiu, Yunxing Shi, Dinglan Zuo, Zhiyu Qiu, Wei He, Yi Niu, Yunfei Yuan, Binkui Li","doi":"10.1186/s13046-024-03134-4","DOIUrl":"10.1186/s13046-024-03134-4","url":null,"abstract":"<p><strong>Background: </strong>The escalating prevalence of metabolic diseases has led to a rapid increase in non-alcoholic steatohepatitis (NASH)-related hepatocellular carcinoma (NASH-HCC). While oxaliplatin (OXA)-based hepatic arterial infusion chemotherapy (HAIC) has shown promise in advanced-stage HCC patients, its efficacy in NASH-HCC remains uncertain. This study aims to assess the effectiveness of OXA-based HAIC and elucidate the mechanisms underlying OXA resistance in NASH-HCC.</p><p><strong>Methods: </strong>The key lncRNAs were screened through RNA-seq analysis of NASH/non-NASH and OXA-sensitive/OXA-resistant (OXA-S/R) HCC tissues. The biological functions of the lnc-OXAR (OXA resistance-related lncRNA in NASH-HCC) in NASH-HCC were verified through a series of in vitro and in vivo experiments. The molecular mechanism of lnc-OXAR was elucidated by fluorescence in situ hybridization, immunoprecipitation-mass spectrometry (FISH), Immunoprecipitation-Mass Spectrometry (IP-MS), RNA pulldown, RNA immunoprecipitation (RIP), methylated RNA immunoprecipitation sequencing (MeRIP-Seq) and a dual-luciferase reporter assay.</p><p><strong>Results: </strong>NASH-HCC exhibited reduced responsiveness to OXA-based HAIC compared to non-NASH HCC. We identified and validated a novel transcript namedlnc-OXAR, which played a crucial role in conferring OXA resistance to NASH-HCC. Inhibition of lnc-OXAR suppressed HCC cell growth and restored OXA sensitivity both in NASH-HCC mouse models and in vitro. Mechanistically, lnc-OXAR recruited Ku70 and cystatin A (CSTA), preventing Ku70 degradation and facilitating DNA double-strand break (DSB) repair, thereby promoting OXA resistance in NASH-HCC. Additionally, WTAP-mediated m<sup>6</sup>A modification enhanced the stability of lnc-OXAR in an IGF2BP2-dependent manner. Notably, silencing lnc-OXAR significantly enhanced the response to OXA in patient-derived xenograft (PDX) models derived from NASH-HCC.</p><p><strong>Conclusions: </strong>The reduced responsiveness of NASH-HCC to OXA treatment can be attributed to the upregulation of lnc-OXAR. Our findings provide a rationale for stratifying HCC patients undergoing OXA-based HAIC based on etiology. Lnc-OXAR holds promise as a novel target for overcoming OXA resistance in NASH-HCC and improving prognosis.</p>","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":null,"pages":null},"PeriodicalIF":11.4,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11271202/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting RBM39 through indisulam induced mis-splicing of mRNA to exert anti-cancer effects in T-cell acute lymphoblastic leukemia. 通过茚虫威诱导 mRNA 的错误拼接来靶向 RBM39,从而在 T 细胞急性淋巴细胞白血病中发挥抗癌作用。
IF 11.4 1区 医学
Journal of Experimental & Clinical Cancer Research Pub Date : 2024-07-24 DOI: 10.1186/s13046-024-03130-8
Tongting Ji, Yang Yang, Juanjuan Yu, Hongli Yin, Xinran Chu, Pengju Yang, Ling Xu, Xiaodong Wang, Shaoyan Hu, Yizhen Li, Xiaochen Wu, Wengyuan Liu, Bi Zhou, Wenjuan Wang, Shuqi Zhang, Wei Cheng, Yanling Chen, Lei Shi, Zhiheng Li, Ran Zhuo, Yongping Zhang, Yanfang Tao, Di Wu, Xiaolu Li, Zimu Zhang, Jun-Jie Fan, Jian Pan, Jun Lu
{"title":"Targeting RBM39 through indisulam induced mis-splicing of mRNA to exert anti-cancer effects in T-cell acute lymphoblastic leukemia.","authors":"Tongting Ji, Yang Yang, Juanjuan Yu, Hongli Yin, Xinran Chu, Pengju Yang, Ling Xu, Xiaodong Wang, Shaoyan Hu, Yizhen Li, Xiaochen Wu, Wengyuan Liu, Bi Zhou, Wenjuan Wang, Shuqi Zhang, Wei Cheng, Yanling Chen, Lei Shi, Zhiheng Li, Ran Zhuo, Yongping Zhang, Yanfang Tao, Di Wu, Xiaolu Li, Zimu Zhang, Jun-Jie Fan, Jian Pan, Jun Lu","doi":"10.1186/s13046-024-03130-8","DOIUrl":"10.1186/s13046-024-03130-8","url":null,"abstract":"<p><strong>Background: </strong>Despite the use of targeted therapeutic approaches, T-cell acute lymphoblastic leukemia (T-ALL) is still associated with a high incidence of complications and a poor prognosis. Indisulam (also known as E7070), a newly identified molecular glue compound, has demonstrated increased therapeutic efficacy in several types of cancer through the rapid degradation of RBM39. This study aimed to evaluate the therapeutic potential of indisulam in T-ALL, elucidate its underlying mechanisms and explore the role of the RBM39 gene.</p><p><strong>Methods: </strong>We verified the anticancer effects of indisulam in both in vivo and in vitro models. Additionally, the construction of RBM39-knockdown cell lines using shRNA confirmed that the malignant phenotype of T-ALL cells was dependent on RBM39. Through RNA sequencing, we identified indisulam-induced splicing anomalies, and proteomic analysis helped pinpoint protein changes caused by the drug. Comprehensive cross-analysis of these findings facilitated the identification of downstream effectors and subsequent validation of their functional roles.</p><p><strong>Results: </strong>Indisulam has significant antineoplastic effects on T-ALL. It attenuates cell proliferation, promotes apoptosis and interferes with cell cycle progression in vitro while facilitating tumor remission in T-ALL in vivo models. This investigation provides evidence that the downregulation of RBM39 results in the restricted proliferation of T-ALL cells both in vitro and in vivo, suggesting that RBM39 is a potential target for T-ALL treatment. Indisulam's efficacy is attributed to its ability to induce RBM39 degradation, causing widespread aberrant splicing and abnormal translation of the critical downstream effector protein, THOC1, ultimately leading to protein depletion. Moreover, the presence of DCAF15 is regarded as critical for the effectiveness of indisulam, and its absence negates the ability of indisulam to induce the desired functional alterations.</p><p><strong>Conclusion: </strong>Our study revealed that indisulam, which targets RBM39 to induce tumor cell apoptosis, is an effective drug for treating T-ALL. Targeting RBM39 through indisulam leads to mis-splicing of pre-mRNAs, resulting in the loss of key effectors such as THOC1.</p>","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":null,"pages":null},"PeriodicalIF":11.4,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11267830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141753261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the impact of GSTM1 as a novel molecular determinant of survival in head and neck cancer patients of African descent. 探索 GSTM1 作为新的分子决定因素对非洲裔头颈癌患者生存期的影响。
IF 11.4 1区 医学
Journal of Experimental & Clinical Cancer Research Pub Date : 2024-07-23 DOI: 10.1186/s13046-024-03127-3
Fan Yang, Fanghui Chen, Chloe Shay, Georgia Z Chen, Nabil F Saba, Yong Teng
{"title":"Exploring the impact of GSTM1 as a novel molecular determinant of survival in head and neck cancer patients of African descent.","authors":"Fan Yang, Fanghui Chen, Chloe Shay, Georgia Z Chen, Nabil F Saba, Yong Teng","doi":"10.1186/s13046-024-03127-3","DOIUrl":"10.1186/s13046-024-03127-3","url":null,"abstract":"<p><strong>Background: </strong>Blacks/African American (BAA) patients diagnosed with head and neck squamous cell carcinoma (HNSCC) have worse survival outcomes than White patients. However, the mechanisms underlying racial disparities in HNSCC have not been thoroughly characterized.</p><p><strong>Methods: </strong>Data on gene expression, copy number variants (CNVs), gene mutations, and methylation were obtained from 6 head and neck cancer datasets. Comparative bioinformatics analysis of the above genomic features was performed between BAAs and Whites. The expression pattern of GSTM1 was validated by immunohistochemistry using tumor tissue microarray (TMA). Effect of GSTM1 knockdown were assessed by cell proliferation, colony formation, and tumor development in an orthotopic mouse model. The changes in protein kinases were determined using the Proteome Profiler Human Phospho-Kinase Array Kit in HNSCC cells with or without GSTM1 knockdown.</p><p><strong>Results: </strong>We identified ancestry-related differential genomic profiles in HNSCC. Specifically, in BAA HNSCC, FAT1 mutations were associated with its gene expression, SALL3 gene expression correlated with its gene CNVs, and RTP4 gene expression showed an inverse correlation with its methylation. Notably, GSTM1 emerged as a prognostic risk factor for BAA HNSCC, with high gene CNVs and expression levels correlating with poor overall survival in BAA patients. Immunohistochemistry results from newly developed in-house TMA validated the expression pattern of GSTM1 between BAA HNSCC and White HNSCC. In an orthotopic mouse model, GSTM1 knockdown significantly inhibited malignant progression in tumors derived from BAAs. In contrast, loss of GSTM1 did not affect the development of HNSCC originating in Whites. Mechanistically, GSTM1 knockdown suppressed HSP27 phosphorylation and β-catenin in BAA HNSCC cells, but not in White HNSCC cells. This differential effect at least partially contributes to tumor development in BAA patients.</p><p><strong>Conclusion: </strong>This study identifies GSTM1 as a novel molecular determinant of survival in HNSCC patients of African descent. It also provides a molecular basis for future research focused on identifying molecular determinants and developing therapeutic interventions to improve outcomes for BAA patients with HNSCC.</p>","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":null,"pages":null},"PeriodicalIF":11.4,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264416/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141753260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
WTAP/IGF2BP3 mediated m6A modification of the EGR1/PTEN axis regulates the malignant phenotypes of endometrial cancer stem cells. WTAP/IGF2BP3介导的EGR1/PTEN轴m6A修饰调节子宫内膜癌干细胞的恶性表型。
IF 11.4 1区 医学
Journal of Experimental & Clinical Cancer Research Pub Date : 2024-07-23 DOI: 10.1186/s13046-024-03120-w
Bo Wang, Yuting Wang, Wantong Wang, Zihao Wang, Yunzheng Zhang, Xin Pan, Xin Wen, Hongrui Leng, Jing Guo, Xiao-Xin Ma
{"title":"WTAP/IGF2BP3 mediated m6A modification of the EGR1/PTEN axis regulates the malignant phenotypes of endometrial cancer stem cells.","authors":"Bo Wang, Yuting Wang, Wantong Wang, Zihao Wang, Yunzheng Zhang, Xin Pan, Xin Wen, Hongrui Leng, Jing Guo, Xiao-Xin Ma","doi":"10.1186/s13046-024-03120-w","DOIUrl":"10.1186/s13046-024-03120-w","url":null,"abstract":"<p><p>Endometrial cancer (EC) stem cells (ECSCs) are pivotal in the oncogenesis, metastasis, immune escape, chemoresistance, and recurrence of EC. However, the specific mechanism of stem cell maintenance in EC cells (ECCs) has not been clarified. We found that WTAP and m6A levels decreased in both EC and ECSCs, and that knocking down WTAP promoted ECCs and ECSCs properties, including proliferation, invasion, migration, cisplatin resistance, and self-renewal. The downregulation of WTAP leads to a decrease in the m6A modification of EGR1 mRNA, and it is difficult for IGF2BP3, as an m6A reader, to recognize and bind to EGR1 mRNA that has lost m6A modification, resulting in a decrease in the stability of EGR1 mRNA. A decrease in the EGR1 level led to a decrease of in the expression tumor suppressor gene PTEN, resulting in deregulation and loss of cellular homeostasis and thereby fostering EC stem cell traits. Notably, the enforced overexpression of WTAP, EGR1, and PTEN inhibited the oncogenic effects of ECCs and ECSCs in vivo, and the combined overexpression of WTAP + EGR1 and EGR1 + PTEN further diminished the tumorigenic potential of these cells. Our findings revealed that the WTAP/EGR1/PTEN pathway is important regulator of EC stem cell maintenance, chemotherapeutic resistance, and tumorigenesis, suggesting a novel and promising therapeutic avenue for treating EC.</p>","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":null,"pages":null},"PeriodicalIF":11.4,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141753262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CXCL5 impedes CD8+ T cell immunity by upregulating PD-L1 expression in lung cancer via PXN/AKT signaling phosphorylation and neutrophil chemotaxis. CXCL5 通过 PXN/AKT 信号磷酸化和中性粒细胞趋化作用上调肺癌中 PD-L1 的表达,从而阻碍 CD8+ T 细胞免疫。
IF 11.4 1区 医学
Journal of Experimental & Clinical Cancer Research Pub Date : 2024-07-22 DOI: 10.1186/s13046-024-03122-8
Dantong Sun, Lipin Tan, Yongbing Chen, Qiang Yuan, Kanqiu Jiang, Yangyang Liu, Yuhang Xue, Jinzhi Zhang, Xianbao Cao, Minzhao Xu, Yang Luo, Zhonghua Xu, Zhonghen Xu, Weihua Xu, Mingjing Shen
{"title":"CXCL5 impedes CD8<sup>+</sup> T cell immunity by upregulating PD-L1 expression in lung cancer via PXN/AKT signaling phosphorylation and neutrophil chemotaxis.","authors":"Dantong Sun, Lipin Tan, Yongbing Chen, Qiang Yuan, Kanqiu Jiang, Yangyang Liu, Yuhang Xue, Jinzhi Zhang, Xianbao Cao, Minzhao Xu, Yang Luo, Zhonghua Xu, Zhonghen Xu, Weihua Xu, Mingjing Shen","doi":"10.1186/s13046-024-03122-8","DOIUrl":"10.1186/s13046-024-03122-8","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer remains one of the most prevalent cancer types worldwide, with a high mortality rate. Upregulation of programmed cell death protein 1 (PD-1) and its ligand (PD-L1) may represent a key mechanism for evading immune surveillance. Immune checkpoint blockade (ICB) antibodies against PD-1 or PD-L1 are therefore widely used to treat patients with lung cancer. However, the mechanisms by which lung cancer and neutrophils in the microenvironment sustain PD-L1 expression and impart stronger inhibition of CD8<sup>+</sup> T cell function remain unclear.</p><p><strong>Methods: </strong>We investigated the role and underlying mechanism by which PD-L1<sup>+</sup> lung cancer and PD-L1<sup>+</sup> neutrophils impede the function of CD8<sup>+</sup> T cells through magnetic bead cell sorting, quantitative real-time polymerase chain reaction (RT-PCR), western blotting, enzyme-linked immunosorbent assays, confocal immunofluorescence, gene silencing, flow cytometry, etc. In vivo efficacy and safety studies were conducted using (Non-obeseDiabetes/severe combined immune deficiency) SCID/NOD mice. Additionally, we collected clinical and prognostic data from 208 patients who underwent curative lung cancer resection between 2017 and 2018.</p><p><strong>Results: </strong>We demonstrated that C-X-C motif chemokine ligand 5 (CXCL5) is markedly overexpressed in lung cancer cells and is positively correlated with a poor prognosis in patients with lung cancer. Mechanistically, CXCL5 activates the phosphorylation of the Paxillin/AKT signaling cascade, leading to upregulation of PD-L1 expression and the formation of a positive feedback loop. Moreover, CXCL5 attracts neutrophils, compromising CD8<sup>+</sup> T cell-dependent antitumor immunity. These PD-L1<sup>+</sup> neutrophils aggravate CD8<sup>+</sup> T cell exhaustion following lung cancer domestication. Combined treatment with anti-CXCL5 and anti-PD-L1 antibodies significantly inhibits tumor growth in vivo.</p><p><strong>Conclusions: </strong>Our findings collectively demonstrate that CXCL5 promotes immune escape through PD-L1 upregulation in lung cancer and neutrophils chemotaxis through autocrine and paracrine mechanisms. CXCL5 may serve as a potential therapeutic target in synergy with ICBs in lung cancer immunotherapy.</p>","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":null,"pages":null},"PeriodicalIF":11.4,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264977/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141735554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma. 更正:在胃癌的临床前模型中,BRD4抑制剂JQ1增强了阿巴西利(abemaciclib)的抗肿瘤疗效。
IF 11.4 1区 医学
Journal of Experimental & Clinical Cancer Research Pub Date : 2024-07-20 DOI: 10.1186/s13046-024-03126-4
Mei Feng, Hao Xu, Wenyuan Zhou, Yisheng Pan
{"title":"Correction: The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma.","authors":"Mei Feng, Hao Xu, Wenyuan Zhou, Yisheng Pan","doi":"10.1186/s13046-024-03126-4","DOIUrl":"10.1186/s13046-024-03126-4","url":null,"abstract":"","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":null,"pages":null},"PeriodicalIF":11.4,"publicationDate":"2024-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141728170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypoxia-enhanced YAP1-EIF4A3 interaction drives circ_0007386 circularization by competing with CRIM1 pre-mRNA linear splicing and promotes non-small cell lung cancer progression. 缺氧增强的YAP1-EIF4A3相互作用通过与CRIM1前mRNA线性剪接竞争而驱动circ_0007386环化,并促进非小细胞肺癌的进展。
IF 11.4 1区 医学
Journal of Experimental & Clinical Cancer Research Pub Date : 2024-07-20 DOI: 10.1186/s13046-024-03116-6
Lixia Li, Dewei Liu, Tingting Chen, Chunhui Wei, Youping Qiao, Weiliang Liu, Yanmei Liang, Zhu Liang, Chunyuan Chen, Dongming Li, Bin Wu, Xuanna Zhao, Dan Huang, Dong Wu
{"title":"Hypoxia-enhanced YAP1-EIF4A3 interaction drives circ_0007386 circularization by competing with CRIM1 pre-mRNA linear splicing and promotes non-small cell lung cancer progression.","authors":"Lixia Li, Dewei Liu, Tingting Chen, Chunhui Wei, Youping Qiao, Weiliang Liu, Yanmei Liang, Zhu Liang, Chunyuan Chen, Dongming Li, Bin Wu, Xuanna Zhao, Dan Huang, Dong Wu","doi":"10.1186/s13046-024-03116-6","DOIUrl":"10.1186/s13046-024-03116-6","url":null,"abstract":"<p><strong>Background: </strong>The progression of non-small cell lung cancer (NSCLC) is significantly influenced by circular RNAs (circRNAs), especially in tumor hypoxia microenvironment. However, the precise functions and underlying mechanisms of dysregulated circRNAs in NSCLC remain largely unexplored.</p><p><strong>Methods: </strong>Differentially expressed circRNAs in NSCLC tissues were identified through high-throughput RNA sequencing. The characteristics of circ_0007386 were rigorously confirmed via Sanger sequencing, RNase R treatment and actinomycin D treatment. The effects of circ_0007386 on proliferation and apoptosis were investigated using CCK8, cloning formation assays, TUNEL staining, and flow cytometry assays in vitro. In vivo, xenograft tumor models were used to evaluate its impact on proliferation. Mechanistically, the regulatory relationships of circ_0007386, miR-383-5p and CIRBP were examined through dual luciferase reporter assays and rescue experiments. Additionally, we detected the binding of EIF4A3 to CRIM1 pre-mRNA by RNA immunoprecipitation and the interaction between YAP1 and EIF4A3 under hypoxic conditions by co-immunoprecipitation.</p><p><strong>Results: </strong>Our investigation revealed a novel circRNA, designated as circ_0007386, that was upregulated in NSCLC tissues and cell lines. Circ_0007386 modulated proliferation and apoptosis in NSCLC both in vitro and in vivo. Functionally, circ_0007386 acted as a sponge for miR-383-5p, targeting CIRBP, which influenced NSCLC cell proliferation and apoptosis via the PI3K/AKT signaling pathway. Furthermore, under hypoxic conditions, the interaction between YAP1 and EIF4A3 was enhanced, leading to the displacement of EIF4A4 from binding to CRIM1 pre-mRNA. This facilitated the back-splicing of CRIM1 pre-mRNA, increasing the formation of circ_0007386. The circ_0007386/miR-383-5p/CIRBP axis was significantly associated with the clinical features and prognosis of NSCLC patients.</p><p><strong>Conclusions: </strong>Circ_0007386, regulated by YAP1-EIF4A3 interaction under hypoxia conditions, plays an oncogenic role in NSCLC progression via the miR-383-5p/CIRBP axis.</p>","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":null,"pages":null},"PeriodicalIF":11.4,"publicationDate":"2024-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141728171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TSP50 facilitates breast cancer stem cell-like properties maintenance and epithelial-mesenchymal transition via PI3K p110α mediated activation of AKT signaling pathway. TSP50通过PI3K p110α介导的AKT信号通路激活,促进乳腺癌干细胞样特性的维持和上皮-间质转化。
IF 11.4 1区 医学
Journal of Experimental & Clinical Cancer Research Pub Date : 2024-07-20 DOI: 10.1186/s13046-024-03118-4
Feng Gao, Sichen Liu, Jing Wang, Gang Wei, Chunlei Yu, Lihua Zheng, Luguo Sun, Guannan Wang, Ying Sun, Yongli Bao, Zhenbo Song
{"title":"TSP50 facilitates breast cancer stem cell-like properties maintenance and epithelial-mesenchymal transition via PI3K p110α mediated activation of AKT signaling pathway.","authors":"Feng Gao, Sichen Liu, Jing Wang, Gang Wei, Chunlei Yu, Lihua Zheng, Luguo Sun, Guannan Wang, Ying Sun, Yongli Bao, Zhenbo Song","doi":"10.1186/s13046-024-03118-4","DOIUrl":"10.1186/s13046-024-03118-4","url":null,"abstract":"<p><strong>Background: </strong>Studies have confirmed that epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC)-like properties are conducive to cancer metastasis. In recent years, testes-specific protease 50 (TSP50) has been identified as a prognostic factor and is involved in tumorigenesis regulation. However, the role and molecular mechanisms of TSP50 in EMT and CSC-like properties maintenance remain unclear.</p><p><strong>Methods: </strong>The expression and prognostic value of TSP50 in breast cancer were excavated from public databases and explored using bioinformatics analysis. Then the expression of TSP50 and related genes was further validated by quantitative RT-PCR (qRT-PCR), Western blot, and immunohistochemistry (IHC). In order to investigate the function of TSP50 in breast cancer, loss- and gain-of-function experiments were conducted, both in vitro and in vivo. Furthermore, immunofluorescence (IF) and immunoprecipitation (IP) assays were performed to explore the potential molecular mechanisms of TSP50. Finally, the correlation between the expression of TSP50 and related genes in breast cancer tissue microarray and clinicopathological characteristics was analyzed by IHC.</p><p><strong>Results: </strong>TSP50 was negatively correlated with the prognosis of patients with breast cancer. TSP50 promoted CSC-like traits and EMT in both breast cancer cells and mouse xenograft tumor tissues. Additionally, inhibition of PI3K/AKT partly reversed TSP50-induced activation of CSC-like properties, EMT and tumorigenesis. Mechanistically, TSP50 and PI3K p85α regulatory subunit could competitively interact with the PI3K p110α catalytic subunit to promote p110α enzymatic activity, thereby activating the PI3K/AKT signaling pathway for CSC-like phenotypes maintenance and EMT promotion. Moreover, IHC analysis of human breast cancer specimens revealed that TSP50 expression was positively correlated with p-AKT and ALDH1 protein levels. Notably, breast cancer clinicopathological characteristics, such as patient survival time, tumor size, Ki67, pathologic stage, N stage, estrogen receptor (ER) and progesterone receptor (PR) levels, correlated well with TSP50/p-AKT/ALDH1 expression status.</p><p><strong>Conclusion: </strong>The effects of TSP50 on EMT and CSC-like properties promotion were verified to be dependent on PI3K p110α. Together, our study revealed a novel mechanism by which TSP50 facilitates the progression of breast cancer, which can provide new insights into TSP50-based breast cancer treatment strategies.</p>","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":null,"pages":null},"PeriodicalIF":11.4,"publicationDate":"2024-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264956/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141728172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promising circulating biomarkers. 胰腺癌前体病变的宏观环境和微观环境之间的交叉对话产生了新的、有前景的循环生物标志物。
IF 11.4 1区 医学
Journal of Experimental & Clinical Cancer Research Pub Date : 2024-07-18 DOI: 10.1186/s13046-024-03117-5
Carla Mottini, Francesca Romana Auciello, Isabella Manni, Christian Pilarsky, Damiano Caputo, Giulio Caracciolo, Alessandro Rossetta, Elena Di Gennaro, Alfredo Budillon, Giovanni Blandino, Maria Serena Roca, Giulia Piaggio
{"title":"The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promising circulating biomarkers.","authors":"Carla Mottini, Francesca Romana Auciello, Isabella Manni, Christian Pilarsky, Damiano Caputo, Giulio Caracciolo, Alessandro Rossetta, Elena Di Gennaro, Alfredo Budillon, Giovanni Blandino, Maria Serena Roca, Giulia Piaggio","doi":"10.1186/s13046-024-03117-5","DOIUrl":"10.1186/s13046-024-03117-5","url":null,"abstract":"<p><p>Pancreatic cancer (PC) is a clinically challenging tumor to combat due to its advanced stage at diagnosis as well as its resistance to currently available therapies. The absence of early symptoms and known detectable biomarkers renders this disease incredibly difficult to detect/manage. Recent advances in the understanding of PC biology have highlighted the importance of cancer-immune cell interactions, not only in the tumor micro-environment but also in distant systemic sites, like the bone marrow, spleen and circulating immune cells, the so-called macro-environment. The response of the macro-environment is emerging as a determining factor in tumor development by contributing to the formation of an increasingly immunogenic micro-environment promoting tumor homeostasis and progression. We will summarize the key events associated with the feedback loop between the tumor immune micro-environment (TIME) and the tumor immune macroenvironment (TIMaE) in pancreatic precancerous lesions along with how it regulates disease development and progression. In addition, liquid biopsy biomarkers capable of diagnosing PC at an early stage of onset will also be discussed. A clearer understanding of the early crosstalk between micro-environment and macro-environment could contribute to identifying new molecular therapeutic targets and biomarkers, consequently improving early PC diagnosis and treatment.</p>","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":null,"pages":null},"PeriodicalIF":11.4,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11256648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141635575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信